Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
126 studies found for:    KLH
Show Display Options
Rank Status Study
1 Terminated
Has Results
A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)
Condition: Autoimmune Disorders
Interventions: Biological: Immucothel Alone (Part A);   Biological: Immucothel+Montanide (Part A);   Biological: Immucothel Alone or Immucothel+Montanide (Part B)
2 Terminated Vaccination With Tetanus and KLH to Assess Immune Responses.
Condition: Cancer
Interventions: Biological: Intracel KLH Vaccine;   Biological: Biosyn KLH;   Drug: Montanide ISA51;   Biological: Tetanus toxoid
3 Completed Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route
Condition: Atopic Dermatitis
Intervention: Biological: KLH carrier-protein
4 Completed Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21
Condition: Prostate Cancer
Intervention: Biological: MUC-2-KLH
5 Active, not recruiting Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
Conditions: Fallopian Tubes Cancer;   Ovarian Cancer;   Peritoneal Cancer
Intervention: Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
6 Completed Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD)
Condition: Dermatitis
Interventions: Other: KLH 0.1 mg;   Other: KLH 5 mg;   Other: PBS (0.1 mL);   Other: Tuberculin PPD
7 Completed Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid
Condition: Lung Cancer
Interventions: Biological: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant;   Biological: Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant
8 Recruiting SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Conditions: Partial Response of Multiple Myeloma or Plasma Cell Leukemia;   Plasma Cell Myeloma
Interventions: Biological: Incomplete Freund's Adjuvant;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Sargramostim;   Biological: SVN53-67/M57-KLH Peptide Vaccine
9 Completed
Has Results
Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma
Condition: Melanoma
Intervention: Biological: KLH conjugates with GD2L and GD3L
10 Completed A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)
Condition: Endometriosis
Interventions: Drug: KLH-2109;   Drug: placebo
11 Completed A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)
Condition: Endometriosis
Intervention: Drug: KLH-2109
12 Completed A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis
Condition: Endometriosis
Intervention: Drug: KLH-2109
13 Active, not recruiting Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine;   Biological: sargramostim;   Biological: aldesleukin;   Other: laboratory biomarker analysis
14 Unknown  Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Biological: Id-KLH
15 Active, not recruiting Id-KLH Vaccine + T Cells
Condition: Multiple Myeloma
Intervention: Biological: CD3/CD28
16 Terminated Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects
Condition: Healthy Adult Volunteers
Interventions: Drug: BMS-986090;   Drug: Placebo matching with BMS-986090;   Drug: Keyhole limpet hemocyanin
17 Recruiting Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis
Condition: Endometriosis
Interventions: Drug: KLH-2109;   Drug: Placebo;   Drug: Leuprorelin acetate
18 Completed
Has Results
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Biological: BG00002 (natalizumab);   Biological: keyhole limpet hemocyanin (KLH);   Biological: tetanus diphtheria toxoid vaccine (Td)
19 Completed Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
Condition: Malignant Neoplasms of Brain
Interventions: Biological: PEP-3-KLH conjugate vaccine;   Biological: daclizumab;   Drug: temozolomide;   Other: placebo;   Biological: PEP-3-KLH
20 Completed Idiotype Vaccine Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients With Lymphoma Who Had Failed Induction Chemotherapy
Condition: Lymphoma
Intervention: Biological: Id-KLH

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years